STING1 and neoplasm: Some small-molecule STING agonists, such as MSA-2, are oral nonnucleotide STING agonists that can effectively stimulate interferon-β secretion in tumors, induce durable tumor regression through antitumor immunity, and have synergistic effects with anti-PD-1 treatment [22].